Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer

Summary

This study is a single-arm, multi-center, open-label prospective phase II clinical study designed to evaluate the efficacy and safety of nab-paclitaxel and S-1 in patients with locally advanced pancreatic cancer. A total of 60 subjects who meet the criteria will be treated with nab-paclitaxel and S-1. The primary endpoint is 6 months progression free survival rate, and secondary endpoints include objective response rate, overall survival, progression free survival and toxicities.

Timeline

Start

2019-05-01

Primary completion

2022-03

Completion

2022-04

Publications

• Cao Z, Qiu J, Luo W, Li J, Chen H, Liu Y, Li S, Li F, Yang Y, Cheng Y, Zhang T, Xue H, Bai C, Zhao Y. Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. Signal Transduct Target Ther. 2026 Jun 22;11(1):243. doi: 10.1038/s41392-026-02741-1.

Drugs

Indications